Li Wu, Li Min, Deng Guangcun, Zhao Liping, Liu Xiaoming, Wang Yujiong
Key Laboratory of Ministry of Education for Conservation and Utilization of Special Biological Resources in Western China, College of Life Science, Ningxia University, Ningxia 750021, P.R. China.
State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, P.R. China.
Mol Med Rep. 2015 Aug;12(2):3073-80. doi: 10.3892/mmr.2015.3770. Epub 2015 May 12.
Tuberculosis (TB) remains to be a prevalent health issue worldwide. At present, Mycobacterium bovis Bacillus Calmette Guerin (BCG) is the singular anti-TB vaccine available for the prevention of disease in humans; however, this vaccine only provides limited protection against Mycobacterium tuberculosis (Mtb) infection. Therefore, the development of alternative vaccines and strategies for increasing the efficacy of vaccination against TB are urgently required. The present study aimed to evaluate the ability of a recombinant adenoviral vector (Ad5-CEAB) co-expressing 10-kDa culture filtrate protein, 6-kDa early-secreted antigenic target, antigen 85 (Ag85)A and Ag85B of Mtb to boost immune responses following primary vaccination with BCG in mice. The mice were first subcutaneously primed with BCG and boosted with two doses of Ad5-CEAB via an intranasal route. The immunological effects of Ad5-CEAB boosted mice primed with BCG were then evaluated using a series of immunological indexes. The results demonstrated that the prime-boost strategy induced a potent antigen-specific immune response, which was primarily characterized by an enhanced T cell response and increased production of cytokines, including interferon-γ, tumor necrosis factor-α and interleukin-2, in mice. In addition, this vaccination strategy was demonstrated to have an elevated humoral response with increased concentrations of antigen-specific bronchoalveolar lavage secretory immunoglobulin (Ig)A and serum IgG in mice compared with those primed with BCG alone. These data suggested that the regimen of subcutaneous BCG prime and mucosal Ad5-CEAB boost was a novel strategy for inducing a broad range of antigen-specific immune responses to Mtb antigens in vivo, which may provide a promising strategy for further development of adenoviral-based vaccine against Mtb infection.
结核病(TB)仍然是全球普遍存在的健康问题。目前,卡介苗(BCG)是唯一可用于预防人类疾病的抗结核疫苗;然而,这种疫苗对结核分枝杆菌(Mtb)感染仅提供有限的保护。因此,迫切需要开发替代疫苗和提高结核病疫苗接种效果的策略。本研究旨在评估一种共表达Mtb的10 kDa培养滤液蛋白、6 kDa早期分泌抗原靶标、抗原85(Ag85)A和Ag85B的重组腺病毒载体(Ad5-CEAB)在小鼠初次接种BCG后增强免疫反应的能力。小鼠首先皮下接种BCG进行初次免疫,然后通过鼻内途径用两剂Ad5-CEAB进行加强免疫。然后使用一系列免疫指标评估用Ad5-CEAB加强免疫的BCG初免小鼠的免疫效果。结果表明,这种初免-加强策略诱导了强烈的抗原特异性免疫反应,其主要特征是小鼠体内T细胞反应增强以及包括干扰素-γ、肿瘤坏死因子-α和白细胞介素-2在内的细胞因子产生增加。此外,与仅用BCG初免的小鼠相比,这种疫苗接种策略在小鼠体内表现出更高的体液反应,抗原特异性支气管肺泡灌洗分泌型免疫球蛋白(Ig)A和血清IgG浓度增加。这些数据表明,皮下BCG初免和黏膜Ad5-CEAB加强免疫的方案是一种在体内诱导对Mtb抗原产生广泛抗原特异性免疫反应的新策略,这可能为进一步开发基于腺病毒的抗Mtb感染疫苗提供一种有前景的策略。